Splenic lymphoma with villous lymphocytes (SLVL) is a recently defined subgroup of chronic B-cell lymphoproliferative diseases. The characteristic morphology of the tumor cells, together with phenotypic and cytogenetic findings, indicate that it is a distinct entity, but the nature of the cell of origin and its relationship to other low-grade lymphomas is unclear. For B-cell tumors, analysis of the variable region heavy chain (V,) genes used to encode the clonal lg has shown marked differences between histologic categories, both in gene usage and extent of somatic mutation. An investigation of V, genes used in five typical cases of SLVL PLENIC LYMPHOMA with villous lymphocytes (SLVL) is a low-grade B-cell lymphoma that usually presents with splenomegaly but no lymphadenopathy.' Patients generally have a slight or moderate lymphocytosis; one diagnostic feature is that the tumor cells display characteristic unevenly distributed thin and short cytoplasmic villi, distinct from those of hairy cell leukemia.' A small percentage of plasma cells or plasmacytoid cells may be present in the blood in SLVL, and monoclonal gammopathy is found in 50% to 60% of cases.* Approximately 70% of cases have an abnormal karyotype with a preponderance of abnormalities involving chromosome llq13, 7q, 17q, and 2pll. In fact, 15% of patients have a t(l1; 14) (q13;q32) translocation involving the BCL-1 locus, which is characteristic of mantle cell lymphoma; however, the rearrangements of the BCL-1 locus in SLVL appear diverse and may be distinct from those of mantle cell lymph~rna.~ Therefore, although SLVL represents a distinct subgroup of B-cell tumors, the nature of the cell of origin and its relationship to other chronic Bcell tumors remains unclear.
PLENIC LYMPHOMA with villous lymphocytes (SLVL) is a low-grade B-cell lymphoma that usually presents with splenomegaly but no lymphadenopathy.' Patients generally have a slight or moderate lymphocytosis; one diagnostic feature is that the tumor cells display characteristic unevenly distributed thin and short cytoplasmic villi, distinct from those of hairy cell leukemia.' A small percentage of plasma cells or plasmacytoid cells may be present in the blood in SLVL, and monoclonal gammopathy is found in 50% to 60% of cases.* Approximately 70% of cases have an abnormal karyotype with a preponderance of abnormalities involving chromosome llq13, 7q, 17q, and 2pll. In fact, 15% of patients have a t(l1; 14) (q13;q32) translocation involving the BCL-1 locus, which is characteristic of mantle cell lymphoma; however, the rearrangements of the BCL-1 locus in SLVL appear diverse and may be distinct from those of mantle cell lymph~rna.~ Therefore, although SLVL represents a distinct subgroup of B-cell tumors, the nature of the cell of origin and its relationship to other chronic Bcell tumors remains unclear.
Analysis of the nucleotide sequences of the variable region genes of the heavy (V,) and light (V,) chains of the clonal Ig synthesised by B-cell tumors is providing information that relates to the cell of origin and its clonal history. For example, comparison of V, sequences in the tumor cell to the corresponding germline gene can show whether the tumor cell has encountered the somatic hypermutation mechanism4 and whether this encounter occurs before or after neoplastic tran~formation.~.' In addition, the distribution of mutations and the ratio of replacement to silent mutations can show whether the tumor cell has been selected by antigen. These data therefore provide a new level of classification of tumors that has biologic implications. This report describes results in SLVL.
S

MATERIALS AND METHODS
Patients and tumor cell analysis. Five patients with clinical features of SLVL were selected for study. The patients appeared typical for SLVL except that only two of the five patients had splenomegaly, which is rather fewer than expected from an 80% incidence of this feature. One of these two patients (patient no. 2, Cytogenetic studies were performed on peripheral blood as described.' Briefly, cells were stimulated with 4-phorb01-12-myristate-13-acetate and harvested after colchicine arrest. A minimum of 10 normal metaphases was demonstrated before a sample was considered normal. Abnormal clones were recognized if two or more cells had the same change.
Preparation of cDNA and DNA. For tumor cells, the VH analysis was performed using RNA as source material, which reduces the possibility of amplifying an aberrantly rearranged VH gene on the allelic chromosome. Total RNA was isolated from the mononuclear cell fraction of the blood using RNAzol B (Cinna Biotecxlabs Inc, Houston, TX). First-strand cDNA was synthesized from S pg of total RNA, using a first-strand synthesis kit and an oligo(dT) primer. Genomic DNA for analysis of germline genes was prepared from tumor cells or from whole blood using the QlAamp blood kit (Qiagen, Hilden, Germany).
Amplijcation of V, genes. For analysis of VH of tumor cells from cDNA, one fifth to one third of a sample of cDNA was amplified by polymerase chain reaction (PCR) using a mixture of oligonucleotide primers specific for each of the VH leader sequences, of VH1-6 families,' together with a mixture of primers complementary to the genomic sequences of the germline J H regions.' For investigation of the germline VH genes that correspond to the tumor-derived genes, it was necessary first to use genomic DNA from tumor cells as a source. with the above primers, to obtain the intron sequences that lie between the VH leader sequence and the S' region of the structural gene." For two of four cases, this procedure identified a matching germline gene from the datahase; however. in two other cases, there was only partial matching to intron sequences in the database. For these. genomic DNA from normal cells from the patient's blood was ;inaly;red by PCR for the unrearranged V,, gene using a primer designed from the intron sequence together with a 3' primer based on the heptamer recombination sequence."' The primer sequences wcre. from patient no. 3. 5"TCATGGGGAACTAGAGATACTG-3': and from patient no. S. 5"ATTCCATCCACTCCTGTGTC-3'.
In a l l cases. PCR was performed in a final volume of SO p L with 2 0 pmol of each primer, SO pmol of dNTPs. and 2.5 U of Taq DNA polymerase with reaction buffer (Boehringer Mannheim UK, Lewes, East Sussex. IJK). Amplitication consisted of an initial denaturation \rep of S minutes at 94°C. followed by 35 cycles of 94°C for 1 minute: 56°C for 1 minute or 52°C for 1 minute for cDNA and DNA. respectively: and 72°C for I minute, with a final extension step of S minutes at 72°C. For each PCR, a control with no added ternplate was used to check for contamination, and repeated separate PCR procedures were performed to ensure that the same product was ObtdiIIed.
Clonin,? cmti .sequencin,? of PCR prodrrct.7. For cloning, gel-puritied products of predicted size were ligated into pGEM-TA vector (Promega. Madison. W1) using 4.5 U of T4 ligase and incubation overnight at 12°C. One third of the ligation mixture was used to transform JM1 09-competent cells (Promega). Clones found to contain ; m insert of appropriate size by restriction analysis of plasmid DNA were sequenced hy the dideoxy chain termination method with T7 DNA polymerase (Pharmacia. Uppsala. Sweden) and the -20 univers:d primer. Sequence alignment analysis was to the database (Entrez Relea\e 11.0; NCBI, Bethesda, MD) and to current databases (V RASE sequence directory, obtainable from Tomlinson et al, MRC
Ccntre for Protein Engineering, Cambridge, UK) using Macvector 4.0 sequence analysis software (Eastman Kodak CO, New Haven. CT).
RESULTS
Prrtients ond clinical moterial. Clinical features and tumor cell phenotypes are shown in Table 1 : all patients had a lymphocytosis. with cells of distinctive villous morphology comprising greater than 20% of the tumor cell population, as assessed by light microscopy. Phenotypic characteristics of the tumor cells were typical of SLVL and included a moderate to strong surface expression of monotypic Ig, together with expression of FMC 7 and CD22 antigens.' The HC-2 antigen, commonly found on cells of hairy cell leukemia: was not detected. In three of five cases, an IgM paraprotein was detected (Table 1) . Karyotypic and cytogenetic analyses were heterogeneous and have been found in other cases of SLVL.' The details of patient no. 4 have been described previously.''
Nucleotide sequence analysis of V , genes of tumor cells. Preparations of cDNA from all five patients were amplified with mixed 5'vH leader-specific primers together with mixed J H primers, and the products were cloned and sequenced. In all cases, a predominant repeated sequence was obtained, consistent with a tumor cell population'*; there were also occasional single different sequences, presumably derived from contaminating normal B cells. Tumor-derived VH-deduced amino acid sequences are shown in Fig 1; nucleotide sequences have been submitted to the EMBL data base (accession numbers for patients no. 1 through 5 are 236888, 236889, 236895, 236887, and 236886, respectively).
Sequence analysis (Table 2) indicates that two of five were derived from the VH1 family and three of five from vH3; all used distinct VH gene segments. Comparison of the sequences with the EMBL/GenBank database of germline genes and with the recently compiled V BASE directory (see Materials and Methods) was made to identify the candidate germline donor VH genes ( Table 2 ). In four of five cases, homology with the donor germline gene was quite low, indicating either a significant degree of somatic mutation or the presence of a novel, possibly polymorphic VH gene in each patient's repertoire. In all cases, the tumor-related sequence represented 80% to 90% of the sequences obtained by PCR and cloning, with other heterogeneous sequences presumed to be derived from normal B cells. Within each of the five tumor-related sequences, even when obtained by more than one PCR, no heterogeneity in nucleotide sequence was detected ( Table 3 ), indicating that there was no ongoing somatic mutation occumng in the tumors.
Investigation of a corresponding germline gene. TO investigate the mutational patterns of the expressed VH genes, it was necessary to delineate the corresponding germline gene sequence. As has been described: the leader intron and S'-flanking nucleotide sequences of rearranged VH genes are less somatically mutated than the coding region, as well as being specific for individual V genes. For patients no. 1, 4, and S , the patients' intron sequences were very close to the assigned germline gene intron sequences, with identity for For personal use only. on October 27, 2017. by guest www.bloodjournal.org From patient no. 1 and a single mismatch for patients no. 4 and 5. For patient no. 3 there were three nucleotide mismatches in the leader intron as compared with the closest germline gene. We therefore amplified the germline gene from patient no. 3's unrearranged DNA (see Materials and Methods) and found the corresponding germline gene to be V1-3b, as assigned from the database. Although there was only one mismatch in the intron sequence for patient no. 5 , we also applied this approach to check assignment and again found correspondence with that assigned from the database. The corresponding germline gene was identified as MTGL.I3
Distribution of mutations in V, sequences. The distribution of the somatic mutations in the expressed tumor-derived VH genes is shown in Table 3 . The data are presented as the numbers of replacement (R) or silent (S) mutations observed in the framework regions (FWR) or the complementaritydetermining regions (CDR1 and CDR2) stretches of the VH gene, as compared with those expected due solely to chance. The number of expected R and S mutations was calculated by assuming that, where n is the number of random mutations, the R mutations should be 0.7511 and the S mutations should be 0.2511: In the absence of selection, the R and S mutations would distribute among the various VH regions according to their respective sizes; therefore, RCoRs = 0.23R and RFWRs = 0.77R. Similarly, ScDRs = 0.23s and SmRa = 0.77s. It is obvious from inspection of Table 3 that for patients no. 1, 4, and 5 there is a clustering of R mutations in the CDRs and that, using the binomial mode1,14 the probability of obtaining the observed clustering due to chance is significantly low ( P < .05). For patient no. 2, there are only three mutations and the value of P is .07, which just fails to reach significance; however, for patient no. 3, who has the highest total number of mutations, there is no significant concentration of R mutations in the CDR. It appears therefore that for three, possibly four, patients there is evidence for a role for antigen in selection of the expressed VH sequences. This conclusion is supported by the fact that the R:S ratios in the CDRs of patients no. 1, 2, 4, and 5 are 8:0, 2:0,5:1, and 5:1, respectively (Table 3) ; because these ratios are greater than 2.9, they are indicative of antigen se1ection.l5 In contrast, for all five patients, the number of R mutations in the FWRs are fewer than would be expected due to chance (Table 3) , and the R:S ratios for patients no. 1, 2, 3, and 5 are 65, O:l, 15:12, and 1 5 , respectively, consistent with preservation of amino acid sequences in these However, for patient no. 4, the R:S ratio of the FWR does reach 3.0 and all the R mutations are in FWR3, a region that may itself contribute to antigen recognition.** CDR3 and .IH regions. Assignment of the CDR3 regions to the corresponding D-segment genes is shown in Fig 2. It appears that usage of D genes is complex, with some indica- For For R-cell tumors. traditionally viewed as being "frozen" at a particular stage of development by neoplastic transformation. analysis of the V-region sequences ofthe clonal Ig is providing information that relates to the cell of origin and to its subsequent history. In the case of follicular lymphoma (FL). the V,, sequences are often somatically mutated and show intraclonal heterogeneity.'"" These features are consistent with the cell of origin having heen exposed to the hypermutation mechanism in the germinal center before neoplastic transformation, hut then remaining under the influence of the mutator after transformation. The fact that in some cases the mutated sequences appear to reflect a role for antigen selection has implications for pathogenesis. because persistent antigen could he "driving" tumor cell In contrast to FL. chronic lymphocytic leukemia (CLL) generally involves cells that have few or no somatic mutations. indicating that the cell of origin has not encountered the hypcrmutation mechanism.'"
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The cell of origin in SLVL is unclear, but phenotypic analysis and the presence of a paraprotein in some cases suggests that it is a mature IgM-positive B cell.'.'.h The location in the spleen and the histologic pattern has indicated a possible relationship to splenic marginal zone lymphoma (MZL), and there is current debate as to whether SLVL represents the leukemic phase of MZL.
In our five random cases of SLVL, analysis of the VIi gene sequences indicates usage of V,,] and VH3 gene families. with a range of gene segments. Because these are the largest families, there is no suggestion from these few cases of bias in V,, usage in SLVL. Other B-cell tumors such as CLL" and FL' do show some bias in V,, gene usage, but more cases of SLVL will have to be accumulated to pursue this point. The nucleotide sequences of the VH genes has shown a relatively consistent pattern, with all the sequences mutated as compared with germline. This can be deduced with confidence. because the corresponding germline gene has heen identified in the patients. This indicates that the cell of origin has been exposed to somatic hypermutation, presumably in the germinal center, which could have occurred in the lymph node or spleen. Another consistent finding is that, in contrast to FL, there is no evidence for intraclonal variation, indicating that the tumor cell in SLVL is no longer influenced by the mutator.
The pattern of mutations is highly suggestive of a role for antigen in selection; for three of five cases this is statistically significant and for one of five cases it is likely. In the case of patient no. 3, however, the VH sequence is highly mutated, but the majority of mutations are in the FWRs. particularly FWR I . The statistical analysis applied to this sequence fails to show a role for antigen selection, but there remains the possibility that sequences in FWR1 can contribute to antigen recognition, either directly, as has been suggested for antired blood cell antibodies," or indirectly by influencing the conformation of the CDRs." Although the analysis of the CDR sequences from patient no. 4 do indicate a role for antigen selection, the R:S ratio of the FWRs is 3.0. with most R mutations in FWR3, perhaps also suggestive of involvement of this region in antigen binding. Clearly more sequence information is needed to improve assessment of antigen selection, but even at this stage, differences between B-cell tumors are emerging.',"' Identification of antigen-selected sequences in SLVL raises the possibility that antigen may influence tumor growth and development, perhaps in a manner similar to the proposed role for bacterial antigens in gastric lymphoma.'? The general pattern of mutations and the lack of intraclonal variation in SLVL is reminiscent of data from multiple myeloma," although so far the selective role of antigen is clearer for SLVL than for myeloma. In summary. it appears that the cell of origin in SLVL is posthypermutation and usually antigen selected. but not class switched, and that it could arise from the hypermutated antigen-responsive IgMpositive memory cells of the germinal center.Ix
